Comment on: “Comparison of Clinical Outcomes Between Ticagrelor and Clopidogrel in East-Asian Patients with Acute Coronary Syndrome: Large Cohort Study”-Reference-Cited by-同舟云学术

Comment on: “Comparison of Clinical Outcomes Between Ticagrelor and Clopidogrel in East-Asian Patients with Acute Coronary Syndrome: Large Cohort Study”

Published:2024-01-25 Issue:2 Volume:24 Page:325-326
ISSN:1175-3277
Container-title:American Journal of Cardiovascular Drugs
language:en
Short-container-title:Am J Cardiovasc Drugs

Author:

Kow Chia Siang^ORCID,Zaihan Abdullah Faiz,Ramachandram Dinesh Sangarran,Hasan Syed Shahzad

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40256-023-00626-0.pdf

Reference6 articles.

1. Park MW. Balancing between ischemic and bleeding risk in PCI patients with ‘bi-risk.’ Korean Circ J. 2022;52(4):338–40.

2. Lee WC, Fang CY, Tsai YH, et al. Comparison of clinical outcomes between ticagrelor and clopidogrel in East-Asian patients with acute coronary syndrome: large cohort study. Am J Cardiovasc Drugs. 2023;23(5):573–81. https://doi.org/10.1007/s40256-023-00603-7.

3. Kubisa MJ, Jezewski MP, Gasecka A, Siller-Matula JM, Postuła M. Ticagrelor—toward more efficient platelet inhibition and beyond. Ther Clin Risk Manag. 2018;14:129–40.

4. Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA. The global burden of cardiovascular diseases and risk: a compass for future health. J Am Coll Cardiol. 2022;80(25):2361–71.

5. Baber U, Leisman DE, Cohen DJ, Gibson CM, Henry TD, Dangas G, et al. Tailoring antiplatelet therapy intensity to ischemic and bleeding risk. Circ Cardiovasc Qual Outcomes. 2019;12(1): e004945.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Author’s Reply to Kow et al.: “Comparison of Clinical Outcomes between Ticagrelor and Clopidogrel in East-Asian Patients with Acute Coronary Syndrome: Large Cohort Study”;American Journal of Cardiovascular Drugs;2024-01-25